RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two approaches ...
Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with ...
Hosted on MSN
Indivior outlines $150M OpEx savings and raises 2025 revenue guidance to $1.22B as SUBLOCADE growth accelerates
The company raised its 2025 guidance, with Ciaffoni indicating, "We now expect total net revenue in 2025 to be up versus 2024, driven by SUBLOCADE growth of 10% at the midpoint." Preblick stated, "Our ...
Indivior PLC is set to report fourth-quarter and full-year 2025 results before the market opens Thursday, February 26, as Wall Street looks for evidence the addiction-treatment specialist can deliver ...
The trial also demonstrated that administering the second SUBLOCADE injection just one week after the first was well tolerated in both treatment arms as the safety profile up to injection two was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results